Engineering Conferences International ECI Digital Archives

Microbial Engineering

Proceedings

3-4-2018

Conference Program

Eli Keshavarz-Moore UCL, United Kingdom

Barry Buckland BiologicB, LLC USA

Follow this and additional works at: http://dc.engconfintl.org/microbial



Part of the Engineering Commons

Recommended Citation

Eli Keshavarz-Moore and Barry Buckland, "Conference Program" in "Microbial Engineering", Prof. Eli Keshavarz-Moore, University College London, England Dr. Barry Buckland, BiologicB, USA Eds, ECI Symposium Series, (2018). http://dc.engconfintl.org/ microbial/66

This Article is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Microbial Engineering by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

Program

Microbial Engineering

March 4-8, 2018 LaFonda on the Plaza - Santa Fe, New Mexico, USA

Conference Chairs

Prof. **Eli Keshavarz-Moore** UCL, United Kingdom

Dr. **Barry Buckland** BiologicB, LLC USA





Engineering Conferences International

32 Broadway, Suite 314 New York, NY 10004, USA Phone: 1-212-514-6760

www.engconfintl.org - info@engconfintl.org

LaFonda on the Plaza 100 E. San Francisco Street Santa Fe, NM 87501 Phone: +1-505-982-5511

www.lafondasantafe.com

Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

ECI BOARD MEMBERS

Barry C. Buckland, President
Mike Betenbaugh
Nick Clesceri
Peter Gray
Michael King
Raymond McCabe
Eugene Schaefer
P. Somasundaran

Chair of ECI Conferences Committee: Nick Clesceri

ECI Technical Liaison for this conference: Beth Junker

ECI Executive Director: Barbara K. Hickernell

ECI Associate Director: Kevin M. Korpics

Organizing Committee

Dicky Abraham (Merck) USA

Arindam Bose (Previously Pfizer, now Consultant), USA

Tim Charlebois (Pfizer) USA

Brigitte Gasser (BOKU) Austria

Akshay Goel (Biologic E) India

Peter Gray (AIBN, University of Queensland) Australia

Wayne Herber (Assembly Biosciences), USA

Beth Junker (BioProcess Advantage LLC), USA

Chris Love (Koch Institute at MIT), USA

Gautam Nayar (BMS), USA

Darren Nesbeth (University College London), UK

Karen Polizzi (IC), UK

Tiffany Rau (BioProcess Technology Consultants (BPTC)), USA
Natarajan Sethuraman (Previously GlycoFi; now Consultant), USA
Daniel Smith (Cobra Biologics), UK
Jim Swartz (Stanford University), USA
Behnam Taidi (CentraleSupélec), France

Conference Sponsors

Amgen

Bill & Melinda Gates Foundation

Biological E Limited

Dyadic International Inc.

Eppendorf AG

GE Healthcare

Genentech

Moderna

Novozymes

Pfizer

Sartorius Stedim Biotech GmbH

Sunday. March 4. 2018

16:00 — 18:00	Conference Check-in
17:45 — 18:00	Welcoming Remarks Barry Buckland and Eli Keshavarz-Moore, Conference Chairs Beth Junker, ECI Technical Liaison
18:00 — 18:50	<u>Plenary Lectures</u> <u>Manufacturing biopharmaceuticals in the age of acceleration</u> Chris Love, Massachusetts Institute of Technology, USA
18:50 — 19:40	Development of live bacterial therapeutics John Aunins, Seres Therapeutics, USA
19:40 — 19:45	Concluding Remarks
19:45 — 20:30	Reception
20:30 - 23:00	Dinner

NOTES

- Technical Sessions will be held in the Ballroom South.
- Poster Sessions will be held in the Ballroom North.
- The ECI office will be in the Stiha Room.
- Meals will be in La Terraza
- Audio, still photo and video recording by any device (e.g., cameras, cell phones, laptops, PDAs, watches) is strictly prohibited during the technical sessions, unless the author and ECI have granted prior permission.
- Speakers Please have your presentation loaded onto the conference computer prior to the session start (preferably the day before).
- Speakers Please leave discussion time as previously directed by your session chair.
- Please do not smoke at any conference functions.
- Turn your mobile telephones to vibrate or off during technical sessions.
- Please write your name on your program so that it can be returned to you if lost or misplaced.
- After the conference, ECI will send an updated participant list to all participants. Please check
 your listing now and if it needs updating, you may correct it at any time by logging into your ECI
 account.

Monday. March 5. 2018

07:00 — 08:30	Breakfast
08:30 — 11:25	Session I: Primary Metabolites Session Chairs: Arindam Bose (AbiologicsB, LLC, USA) Brigitte Gasser (BOKU, Austria)
08:30 — 08:35	Session Introduction
08:35 — 09:10	Metabolic engineering strategies for producing oleochemicals in bacteria Brian F. Pfleger, University of Wisconsin-Madison, USA
09:10 — 09:45	Improving biochemical yields with MixoFerm Shawn W. Jones, White Dogs Labs, USA
09:45 — 10:00	Cyanobacteria as photosynthetic factories: Synthetic biology methods in the development of next-generation production platforms Hariharan Dandapani, University of Turku, Finland
10:00 — 10:30	Coffee break
10:30 — 10:55	Systems metabolic engineering of <i>Corynebacterium</i> glutamicum and <i>Bacillus methanolicus</i> for production of new products from alternative carbon sources Volker F. Wendisch, Bielefeld University, Germany
10:55 — 11:20	MOMENTUM: Microbial Optimization via Metabolic Network Minimization Zhixia Ye, Duke University, USA
11:20 — 11:25	Concluding Remarks
11:25 — 11:30	Introduction of Plenary Lecture – Barry Buckland
11:30 — 12:20	Plenary Lecture New bio-based supply chains for plant-based medicines Christina Smolke, Antheia, USA
12:20 — 12:25	Concluding Remarks
12:30 — 14:30 14:30 — 16:25	Lunch Session II: Therapeutic Proteins (Part 1) (Sponsored by Sartorius Stedim Biotech GmbH) Session Chairs: Karen Polizzi (Imperial College London, United Kingdom) Eli Keshavarz-Moore (UCL, United Kingdom) Michael Hohn (Merck, USA)
14:30 — 14:35	Session Introduction
14:35 — 15:10	Learning from the mammalian expression system to develop a high titer- half antibody process in <i>E. coli</i> Emily Dong, Genentech, USA
15:10 — 15:35	Matching secretion capacity via translation control Neil Dixon, Manchester University, United Kingdom

Monday. March 5. 2018 (continued)

15:35 — 16:00	C1: How the C1 platform will change the production approach for therapeutic proteins Ronen Tchelet, Dyadic, USA
16:00 — 16:20	Gram Level scFv expression platform of <i>Pichia pastoris</i> Jen-Wei Chang, Development Center for Biotechnology, Taiwan
16:20 — 16:25	Concluding Remarks
16:25 — 16:55	Coffee/Tea break
16:55 — 17:00	Introduction of Plenary Lecture – Eli Keshavarz-Moore
17:00 — 17:50	Plenary Lecture mRNA vaccines and therapeutics: On the progress from promise to reality Hari Pujar, Moderna, USA
19:00 — 20:30	Dinner
20:30 — 23:00	Poster Session I (with social hour and dessert) Session Chairs: Stefanie Frank (UCL, United Kingdom) Eli Keshavarz-Moore (UCL, United Kingdom)

Tuesday, March 6, 2018

07:00 - 08:30	Breakfast
08:30 — 12:30	Session III: Secondary Metabolites Session Chairs: Beth Junker (Bioprocess Advantage, USA) Yi Tang (University of California, Los Angeles, USA)
08:30 - 08:35	Session Introduction
08:35 — 09:05	Natural products by synthetic biology and microbial engineering Ben Shen, The Scripps Research Institute, USA
09:05 — 09:35	An integrated strain improvement and process development program for the production of UK-2A, the precursor of the fungicide Inatreq [™] active Mark Mikola, Dow AgroSciences LLC, USA
09:35 — 10:05	Scale up of low producing, potent secondary metabolites Scott Doncaster, BioVectra Inc., Canada
10:05 — 10:25	One-pot synthesis of amino-alcohol using a <i>de novo</i> transketolase: Transaminase pathway in <i>Pichia pastoris</i> strain GS115 Marie-Jose Henriquez, UCL, United Kingdom
10:25 — 10:55	Coffee/Tea break (Sponsored by Amgen)
10:55 — 11:25	Microbial engineering of new <i>streptomyces sp.</i> from extreme environments for novel antibiotics and anticancer drugs Juan Asenjo, University of Chile, Chile
11:25 — 11:55	Genome-guided methods for discovering new natural product from fungi Yi Tang, University of California, Los Angeles, USA
11:55 — 12:25	An efficient commercial platform for microbial engineering of natural products Hsien-Chung Tseng, Manus Bio, USA
12:25 — 12:30	Concluding Remarks
12:30 — 14:00	Lunch
14:00 — 14:05	Introduction of Plenary Lecture – Barry Buckland
14:05 — 15:00	Plenary Lecture Engineered polyketide synthases for production of commodity and specialty chemicals Jay Keasling, University of California-Berkeley, USA
15:00 — 15:30	Coffee/Tea break (Sponsored by Genentech)
15:30 — 17:35	Session IV: Biomaterials and Biofuels Session Chairs: Behnam Taidi (CentraleSupélec, LGPM, France) Joel Cherry (Amyris Inc., USA)
15:30 — 15:35	Session Introduction

Tuesday, March 6, 2018 (continued)

15:35 — 16:05	Integrated bioengineering: Genomatica's approach to rapid commercialization Michael Japs, Genomatica, USA
16:05 – 16:45	Automating bioengineering: First the hands, then the head Ben Kaufmann-Malaga, Amyris, USA
16:45 – 17:15	The circular bioeconomy and the concept of biorefinery Behnam Taidi, CentraleSupélec, LGPM, France
17:15 – 17:30	Exploiting fatty acid metabolic pathway for production of short chain fatty acids in <i>E. coli</i> Kamran Jawed, ICGEB/Rensselaer Polytechnic Institute, USA
17:30 – 17:35	Concluding Remarks
17:35 – 20:30	"Dine Around" (free time for participants to experience Santa Fe dining)
20:30 – 23:00	Poster Session II Session Chairs: Stefanie Frank (UCL, United Kingdom) Eli Keshavarz-Moore (UCL, United Kingdom)

Wednesday, March 7, 2018

07:00 — 08:30	Breakfast
08:30 — 10:30	Session V: Therapeutics Proteins (Part II) Session Chairs: Karen Polizzi (Imperial College London, United Kingdom) Eli Keshavarz-Moore (UCL, United Kingdom) Michael Hohn (Merck, USA)
08:30 - 08:35	Session Introduction
08:35 — 09:10	Antibody production in micro-organisms Hanxiao Jiang, Amyris Inc., USA
09:10 — 09:40	Process optimization, manufacturing changes from early to late phase development, and comparability of Resolaris Ying Buechler, aTyr Pharma, USA
09:40 — 10:10	Promoter and process engineering for recombinant protein production in <i>Pichia pastoris</i> towards simple, fast and methanol-free cultivation regimes and high product titers Roland Prielhofer, ACIB, Austria
10:10 — 10:25	Towards extracellular release of recombinant proteins from <i>E.coli</i> using antisense technology Shahin Heshmatifar, UCL, United Kingdom
10:25 — 10:30	Concluding Remarks
10:30 — 11:00	Coffee/Tea break (Sponsored by Biological E Limited)
11:00 — 12:30	Session VI: Vaccines (Sponsored by Pfizer) Session Chairs: Barry Buckland (BiologicB, LLC, United Kingdom) Tiffany Rau (BioProcess Technology Consultants (BPTC), USA)
11:00 — 11:05	Session Introduction
11:05 — 11:40	Rational design of expression vectors for high quality biologics Kerry Love, Massachusetts Institute of Technology, USA
11:40 — 12:00	High yield plasmid DNA production under oxygen limitation using microaerobically induced replication Alvaro Lara, Universidad Autónoma Metropolitana-Cuajimalpa, Mexico
12:00 — 12:30	A Pseudomonas fluorescens- based platform for robust vaccine manufacturing Russell Coleman, Pfenex Inc, USA
12:30 — 14:00	Lunch
14:00 — 14:05	Introduction
14:05 — 14:30	Enhancing the yield and quality of supercoiled plasmid through Plasmid Engineering Olusegun Folarin, UCL, UK

Wednesday. March 7. 2018 (continued)

14:30 — 15:00	Computational fluid dynamics modeling for fermentation risk reduction during technology transfer and risk understanding Tracie Spangler, Merck & Co., Inc., USA
15:00 — 15:30	Engineering of probiotic <i>E.coli</i> to treat metabolic disorders Paul Miller, Synlogic, USA
15:30 — 15:35	Concluding Remarks
15:35 — 16:00	Coffee/Tea break
16:00 — 18:15	Conference Workshop Chair: Eli Keshavarz-Moore (UCL, United Kingdom)
	Topic: Leap-frogging microbial fermentation applications-what is needed, who can develop it, and how will it move the dial?
16:00 — 16:05	Introduction
16:05 — 16:15	Historical Perspective: Barry Buckland (BiologicB, LLC)
16:15 — 16:35	Present Day: Equipment - Vendors and CMOs Sartorius, GE
16:35 — 16:45	Present Day: Cost models; Buy versus build Tiffany Rau, BioProcess Technology Consultants (BPTC), USA
16:45 — 16:55	Present Day: Secondary metabolites and chemicals Joel Cherry, Amyris Inc., USA
16:55 — 17:05	A vision for therapeutic proteins and vaccine protein antigens Chris Love, Massachusetts Institute of Technology, USA
17:05 — 17:15	Impact on human health: The unmet medical need is often affordability Steve Hadley, Bill & Melinda Gates Foundation, USA
17:15 - 17:30	Role of Academia/Government/Industry Partnership NIIMBL, UCL Biomanufacturing Hub Barry Buckland, Eli Keshavarz-Moore
17:30 — 18:10	Open Discussion
18:10 — 18:15	Concluding Remarks
18:15 — 18:30	Short biobreak
18:30 — 18:35	Introduction to Closing Lecture - Eli Keshavarz-Moore

Wednesday, March 7, 2018 (continued)

18:35 — 19:10	Closing Plenary Lecture Opening microbial cells expands their capabilities Jim Swartz, Stanford University, USA
19:45 — 23:00	Reception, Banquet Dinner and Poster Prizes

Thursday. March 8. 2018

07.00 - 09.30

Breakfast and Departures

Poster Presentations

 Enlarging the synthetic biology toolbox for *Pichia pastoris*: Golden Gate cloning and CRISPR/Cas9

Roland Prielhofer, ACIB - Austrian Centre of Industrial Biotechnology, BOKU/DBT, Austria

2. Engineering vacuolar sorting pathways for efficient secretion of recombinant proteins

Brigitte Gasser, BOKU/DBT, Austrian Centre for Industrial Biotechnology (ACIB), Austria

3. Genome-scale reconstruction of *Salinispora tropica* metabolism; Microbial engineering and its applications in secondary metabolite production
Barbara A. Andrews, Centre for Biotechnology and Bioengineering, University of Chile, Chile

4. Using screening and classical strain improvement techniques to get the best performance of lactic acid bacteria

Gunnar Øregaard, Chr Hansen, Denmark

 Combined engineering of disaccharide transport and phosphorolysis for enhanced ATP yield from sucrose fermentation in Saccharomyces cerevisiae Wesley Marques, Delft University of Technology, The Netherlands

- 6. **Engineering of** *Escherichia coli* **protein expression process development** Chih-Hsi Fan, Development Center for Biotechnology, Taiwan
- 7. **Gram level scFv expression platform of** *Phichi pastoris*Jen-Wei Chang, Development Center for Biotechnology / Institute of Biologics, Taiwan
- 8. Redox potential control in anaerobic Clostridium beijerinckii fermentation using single-use vessels

Ying Yang, Eppendorf Inc., USA

Production, immobilization and synthesis of pharmacological derivatives of lipase B from Candida antarctica in Pichia pastoris
 Julia Robert, Federal University of Rio de Janeiro, Brazil

- 10. **Improvement of retinoids production in recombinant** *E. coli* **using glyoxylic acid** Ji-Bin Park, Gyeongsang National University, South Korea
- 11. Sequential whole cell conversion process for production of D-psicose and D-mannitol from D-fructose

Seong-Hee Jeong, Gyeongsang National University, South Korea

12. Optimization of isoprene production using a metabolically engineered *Escherichia Coli*

Seon-Yeong Jo, Gyeongsang National University, South Korea

- 13. **Production of α-Bisabolol from metabolically engineered** *Escherichia coli* Ju-Eon Park, Gyeongsang National University, South Korea
- 14. Engineering of Corynebacterium glutamicum for the secretory production of recombinant proteins via Tat-dependent pathway

 Jae Woong Choi, KAIST, South Korea

- 15. **Expression and downstream purification of insulin molecules in** *Pichia pastoris* Aster J. Escalante, Keck Graduate Institute, USA
- 16. Replacing animal-based hydrolysates in biopharmaceutical processes with animal-free and chemically defined alternatives to reduce regulatory concerns
 Floyd L. Inman III, Kerry, USA
- 17. Synthetic biocatalytic modules for enhanced transformation of biological waste products

Peter L. Bergquist, Macquarie University, Australia

- 18. **Identifying the best** *Pichia pastoris* **base strain using functional genomics**Joseph R. Brady, Massachusetts Institute of Technology, USA
- Case study: Raman implementation for process lifecycle management in fermentation based processes Roberto I. Ortiz, Merck & Co, USA
- 20. E. coli strain engineering to minimize host cell protein contamination of recombinant target protein

James Samuelson, New England Biolabs, Inc., USA

- 21. Sustainable production of β-Xanthophylls in *Saccharomyces Cerevisiae* Vicente Cataldo, Pontificia Universidad Católica de Chile, Chile
- 22. Coenzyme Q production by metabolic engineered *Escherichia coli* strains Irene Martinez, Pontificia Universidad Católica de Valparaíso, Chile
- 23. Automation and miniaturization of a microbial fermentation platform for the production of antibody fragments
 Geoff Brown, UCB, United Kingdom
- 24. Genetically engineered probiotic *E. coli* Nissle to consume amino acids associated with orphan metabolic diseases
 Ning Li, Synlogic Inc., USA
- 25. Towards extracellular release of recombinant proteins from E.coli using antisense technology
 Shahin Heshmatifar, UCL, United Kingdom
- 26. Effect of the oxygen transfer rate on oxygen-limited production of plasmid DNA by Escherichia coli

Alvaro R. Lara, Universidad Autónoma Metropolitana-Cuajimalpa, Mexico

 Methodology to rapidly assess enzyme cascades in aid of metabolic engineering of host cells

Maria Villegas-Torres, Icesi University and University College London, Colombia

28. Enhancing the productivity of supercoiled plasmid upstream bioprocessing through plasmid engineering

Olusegun Folarin, University College London, United Kingdom

29. **Developing bacterial microcompartments for the recombinant production of proteins** Stefanie Frank, University College London, United Kingdom

30. From screening to process optimization: AMBR technology to speed up microbial fermentation processes

Kevin McHugh, Sartorius Stedim Biotech, USA

31. Enumeration method and medium design for a mixed culture of saccharomyces cerevisiae and chlorella vulgaris

Behnam Taidi, CentraleSupélec, LGPM, France